December 5, 2022
Kidswell Bio Corporation
Code: 4584 (TSE Mothers)
Masaharu Tani, President & CEO

Announcement of participation in the open innovation initiative “i2.JP (Innovation InfusionJapan)” led by AstraZeneca K.K.
Tokyo, December 5, 2022 – Kidswell Bio Corporation (KWB) is delighted to announce that KWB participatedin the open innovation initiative in healthcare field “i2.JP (Innovation Infusion Japan)” led by AstraZeneca K.K.
(Headquarters in Kita-ku, Osaka, Takafumi Horii, Representative Director and President) as a partnercompany.
With the mission of healthcare innovation engine to realize “patient centricity”, i2.JP is an open innovation
initiative to connect healthcare professionals, local governments, academia and private companies, designed
to jointly work out collective and practical optimal answers toward the solution of issues in the healthcare
field.
KWB has been conducting cell therapy (regenerative medicine) business utilizing stem cells from human
exfoliated deciduous teeth (SHED) as a growth driver to improve KWB’s corporate value and accelerating
research and development to launch cell/gene therapy for pediatric, rare and intractable diseases with SHED
master cell bank (MCB) completed in August 2022. As a partner company, KWB will actively collaborate
with AstraZeneca, other partner companies and organizations involved in this initiative, and will tackle fourchallenges (1. realize “patient centricity”, 2. deliver added value solution to healthcare professionals, 3.
discover and develop new technologies contributing to patients and healthcare professionals, 4. optimize
healthcare systems) through KWB’s cell therapy (regenerative medicine) business.
Related press releases and presentations:-[Presentation] Medium Term Strategic Plan -KWB2.0https://www.kidswellbio.com/Portals/0/resources/pdf/en/Presentation_KWB%202.0%20Full%20version_ENG.pdf?TabModule583=0-

Announcement of completion of SHED Master Cell Bank in compliance with GMP
https://www.kidswellbio.com/Portals/0/20220831_SHED%20MCB%20Press%20Release.pdf?TabModul
e583=0-[Presentation] SHED Master Cell Bank completed
https://www.kidswellbio.com/Portals/0/resources/pdf/en/20220831_SHED%20MCB%20Presentation.pdf?TabModule583=0-

Announcement of a patent application on cell therapy for cerebral palsy utilizing SHED with Tokai
National Higher Education and Research System
https://www.kidswellbio.com/Portals/0/resources/pdf/en/20221024_01.pdf?TabModule583=0-

Announcement of publication of the research articles in collaboration with Hamamatsu University
School of Medicine
https://www.kidswellbio.com/Portals/0/resources/pdf/en/20221107_01.pdf?TabModule583=0-

Announcement of publication of the third research article in collaboration with Hamamatsu University
School of Medicine
https://www.kidswellbio.com/Portals/0/resources/pdf/en/20221128_02.pdf?TabModule583=0

About Kidswell Bio Corporation (KWB)
Kidswell Bio Corporation will challenge pediatric disease as a new field, in addition to intractable and rarediseases on which KWB has also been focusing for R&D. We would like to contribute to children who havehopes and dreams for their bright future. Furthermore, with our biotech expertise and children’s potential
vital force such as SHED, we envision creating new pharmaceuticals and therapeutics for all people under“Kids Well, All Well.”Contact:
Kidswell Bio Corporation
Tel: +81-3-6222-9547

Mail: info@kidswellbio.com

2